BD BBL Sensi Disc Ofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231672®
Published February 14, 2024 · Recall initiated: January 8, 2024
Summary
FDA records medical device Class II recall Z-1036-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 2,363,168 total units; Lot: Catalog No. 231672® UDI-DI 30382902316726 Lots 1305177 2039254 2180484 2304476. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Becton Dickinson & Co.
- Distributor
- Domestic distribution nationwide. International distribution worldwide.
- Lot
- Catalog No. 231672® UDI-DI 30382902316726 Lots 1305177 2039254 2180484 2304476
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.October 21, 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.October 21, 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic useMay 6, 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic useMay 6, 2026
- FDABD BBL Sensi Disc Moxifloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. CatalogFebruary 14, 2024
- FDABD BBL Sensi Disc Piperacillin/Tazobactam- 100/10 ug, used for semi-quantitative in vitro susceptibilityFebruary 14, 2024
Questions about this recall
Was BD BBL Sensi Disc Ofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231672® recalled?
Yes. FDA published recall Z-1036-2024 on February 14, 2024. Reported hazard: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What should I do if I have this product?
Voluntary: Firm initiated · Letter